Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 5/20 | 0.43 |
| ▸ | LTC4S | Q16873 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743159 | 0.90 | LMNA (0.46) | L3MBTL1LMNALPAR1LPAR5LTC4S | |
| SCHEMBL233238 | 0.88 | SRD5A2 (0.51) | L3MBTL1LMNALTC4SMAPTSMN1; SMN2 | |
| SCHEMBL2743161 | 0.85 | LMNA (0.48) | L3MBTL1LMNALTC4SMAPTSMN1; SMN2 | |
| SCHEMBL2743160 | 0.82 | MRGPRX4 (0.45) | L3MBTL1LMNALPAR1LPAR5LTC4S | |
| SCHEMBL230136 | 0.81 | SRD5A2 (0.51) | L3MBTL1LMNALTC4SSRD5A2HPGD | |
| SCHEMBL2743156 | 0.80 | LTC4S (0.49) | L3MBTL1LMNALPAR1LPAR5LTC4S | |
| SCHEMBL231355 | 0.80 | LTC4S (0.46) | L3MBTL1LMNALTC4SSRD5A2HPGD | |
| SCHEMBL232237 | 0.80 | SRD5A2 (0.56) | L3MBTL1LMNALTC4SMAPTSMN1; SMN2 | |
| SCHEMBL230420 | 0.79 | LTC4S (0.43) | L3MBTL1LMNALTC4SMAPTSMN1; SMN2 | |
| SCHEMBL2743158 | 0.78 | SRD5A2 (0.47) | L3MBTL1LMNALTC4SMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | L3MBTL1 324/4885LMNA 1141/4885LPAR1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.